Cargando…

Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS)

BACKGROUND: Alzheimer's Disease, the leading cause of dementia, is over-represented in females. The apolipoprotein E (APOE)ε4 allele is the strongest genetic risk factor for late-onset AD and is associated with aberrant cerebrospinal fluid levels (CSF) of total tau (t-tau), phosphorylated tau (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saunders, Tyler S., Jenkins, Natalie, Blennow, Kaj, Ritchie, Craig, Muniz-Terrera, Graciela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440380/ https://www.ncbi.nlm.nih.gov/pubmed/36041266 http://dx.doi.org/10.1016/j.ebiom.2022.104241

Ejemplares similares

Mediterranean diet score is associated with greater allocentric processing in the EPAD LCS cohort: A comparative analysis by biogeographical region
por: Gregory, Sarah, et al.
Publicado: (2022)

European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (EPAD LCS): study protocol
por: Solomon, Alina, et al.
Publicado: (2018)

Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort
por: Ingala, Silvia, et al.
Publicado: (2021)

Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings
por: Vermunt, Lisa, et al.
Publicado: (2020)

Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review
por: Saunders, Tyler S., et al.
Publicado: (2022)

Self‐reported diabetes is associated with allocentric spatial processing in the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study
por: Gregory, Sarah, et al.
Publicado: (2022)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles
por: Delaby, Constance, et al.
Publicado: (2022)

Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research
por: Ritchie, Craig W, et al.
Publicado: (2015)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

The Open-Access European Prevention of Alzheimer’s Dementia (EPAD) MRI dataset and processing workflow
por: Lorenzini, Luigi, et al.
Publicado: (2022)

A Comparison of Cerebrospinal Fluid Beta-Amyloid and Tau in Idiopathic Normal Pressure Hydrocephalus and Neurodegenerative Dementias
por: Said, Harun Muayad, et al.
Publicado: (2022)

CSF tau and β-amyloid as biomarkers for mild cognitive impairment
por: Hampel, Harald, et al.
Publicado: (2004)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Molecular Mechanisms of Anticancer Activity of N-Glycosides of Indolocarbazoles LCS-1208 and LCS-1269
por: Zenkov, Roman G., et al.
Publicado: (2021)

Involving research participants in a pan-European research initiative: the EPAD participant panel experience
por: Gregory, S., et al.
Publicado: (2020)

What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study
por: Watson, Julie, et al.
Publicado: (2019)

Application of Big Data and Artificial Intelligence technologies to dementia prevention research: an opportunity for low-and-middle-income countries
por: Danso, Samuel O, et al.
Publicado: (2019)

Tau oligomers in cerebrospinal fluid in Alzheimer's disease
por: Sengupta, Urmi, et al.
Publicado: (2017)

Heteromers of amyloid precursor protein in cerebrospinal fluid
por: Cuchillo-Ibañez, Inmaculada, et al.
Publicado: (2015)

Performance on a pattern separation task by Alzheimer’s patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E ∈4 status and cerebrospinal fluid amyloid-β42 levels
por: Wesnes, Keith A, et al.
Publicado: (2014)

ePAD: An Image Annotation and Analysis Platform for Quantitative Imaging
por: Rubin, Daniel L., et al.
Publicado: (2019)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels
por: Bloniecki, Victor, et al.
Publicado: (2014)

Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease
por: Gangishetti, Umesh, et al.
Publicado: (2018)

Elevated amyloid beta peptides and total tau in cerebrospinal fluid in individuals with Creatine transporter deficiency
por: Rahhal, Samar, et al.
Publicado: (2023)

Decreased levels of soluble amyloid β-protein precursor and β-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus
por: Trysberg, Estelle, et al.
Publicado: (2004)

Developing an Explainable Machine Learning-Based Personalised Dementia Risk Prediction Model: A Transfer Learning Approach With Ensemble Learning Algorithms
por: Danso, Samuel O., et al.
Publicado: (2021)

Abnormal CSF amyloid-β42 and tau levels in hip fracture patients without dementia
por: Oh, Esther S., et al.
Publicado: (2018)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid
por: Selnes, Per, et al.
Publicado: (2010)

Glycan biomarkers for Alzheimer disease correlate with T‐tau and P‐tau in cerebrospinal fluid in subjective cognitive impairment
por: Schedin‐Weiss, Sophia, et al.
Publicado: (2020)

Synthetic standard aided quantification and structural characterization of amyloid-beta glycopeptides enriched from cerebrospinal fluid of Alzheimer’s disease patients
por: Nilsson, Jonas, et al.
Publicado: (2019)

Understanding and predicting the longitudinal course of dementia
por: Melis, René J.F., et al.
Publicado: (2019)

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders
por: Irwin, David J., et al.
Publicado: (2018)

Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
por: Han, Jiajun, et al.
Publicado: (2021)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
por: Maxwell, Taylor J., et al.
Publicado: (2018)

Comparison of Cox proportional hazards regression and generalized Cox regression models applied in dementia risk prediction
por: Goerdten, Jantje, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ep6c0pthlqmmhlpvirf66blec0